FDA advisers narrowly back first gene therapy for muscular dystrophy

In a close vote, advisers to the Food and Drug Administration recommended approval of a gene therapy for muscular dystrophy developed by Sarepta Therapeutics.Sarah Silbiger/Getty Images In a split vote, advisers to the Food and Drug Administration recommended that the agency approve the first gene therapy for Duchenne muscular dystrophy, the most common form of the genetic illness.

Read at www.npr.org